Albert David Ltd (IN:ALBERTDAVD)
:ALBERTDAVD
Top Page
Albert David Ltd
(ALBERTDAVD)
Select Model
Select Model
Rating:51Neutral
Price Target:
₹673.00
▼(-14.64% Downside)
Action:ReiteratedDate:11/25/25
Albert David Ltd's overall stock score is primarily impacted by its strong balance sheet, which is overshadowed by declining financial performance and bearish technical indicators. The negative P/E ratio and low dividend yield further weigh on the valuation.
Positive Factors
Strong balance sheet
Low leverage and a robust equity ratio provide durable financial flexibility. With limited debt service requirements the company can fund operations, capex, or withstand cyclical pharmaceutical demand shocks without immediate refinancing pressure, supporting multi-month resilience.
Negative Factors
Declining revenue
Double-digit revenue contraction and severe EPS decline signal weakening market traction or pricing pressure. Persisting top-line shrinkage erodes scale benefits, limits fixed-cost absorption, and undermines the firm's ability to restore margins and invest for medium-term growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Low leverage and a robust equity ratio provide durable financial flexibility. With limited debt service requirements the company can fund operations, capex, or withstand cyclical pharmaceutical demand shocks without immediate refinancing pressure, supporting multi-month resilience.
Read all positive factors
Albert David Ltd (ALBERTDAVD) vs. iShares MSCI India ETF (INDA)
Market Cap
₹4.19B
Dividend Yield0.66%
Average Volume (3M)210.00
Price to Earnings (P/E)6.9
Beta (1Y)1.18
Revenue Growth-13.51%
EPS Growth-122.00%
CountryIN
Employees1,497
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)26.82
Shares Outstanding5,707,162
10 Day Avg. Volume184
30 Day Avg. Volume210
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)1.21
Price to Sales (P/S)1.37
P/FCF Ratio-10.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Albert David Ltd Business Overview & Revenue Model
Company Description
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles in India. It offers formulations for parenterals, oral/enteral, topical agents, a...
How the Company Makes Money
The company makes money primarily by selling pharmaceutical formulations. Revenue is generated through (1) domestic sales to healthcare channels (such as distributors/stockists, pharmacies, and institutional customers) for branded and/or generic f...
Albert David Ltd Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
78
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.16B | 3.46B | 3.60B | 3.42B | 3.12B | 2.46B |
| Gross Profit | 1.75B | 2.29B | 2.32B | 2.18B | 1.95B | 1.58B |
| EBITDA | -359.98M | 30.26M | 1.05B | 598.68M | 567.76M | 364.59M |
| Net Income | -150.80M | 172.01M | 754.20M | 361.75M | 352.58M | 221.43M |
Balance Sheet | ||||||
| Total Assets | 5.33B | 5.11B | 4.98B | 4.23B | 4.03B | 3.41B |
| Cash, Cash Equivalents and Short-Term Investments | 2.84B | 2.44B | 2.85B | 2.03B | 1.75B | 1.49B |
| Total Debt | 414.14M | 123.17M | 33.24M | 53.18M | 56.62M | 16.19M |
| Total Liabilities | 1.39B | 1.19B | 1.15B | 1.12B | 1.23B | 970.20M |
| Stockholders Equity | 3.94B | 3.92B | 3.83B | 3.12B | 2.79B | 2.44B |
Cash Flow | ||||||
| Free Cash Flow | -271.21M | -432.92M | 346.28M | 52.78M | 292.83M | 349.79M |
| Operating Cash Flow | -208.45M | -284.36M | 455.02M | 105.15M | 403.65M | 366.11M |
| Investing Cash Flow | -46.97M | 233.01M | -332.48M | -49.95M | -396.97M | -366.84M |
| Financing Cash Flow | 248.82M | 1.10M | -82.70M | -63.62M | -12.59M | -17.05M |
Albert David Ltd Technical Analysis
Positive
788.40
Price Trends
685.80
Positive
723.20
Positive
779.45
Negative
Market Momentum
-4.92
Negative
63.22
Neutral
86.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Positive. The current price of 788.4 is above the 20-day moving average (MA) of 659.25, above the 50-day MA of 685.80, and above the 200-day MA of 779.45, indicating a neutral trend. The MACD of -4.92 indicates Negative momentum. The RSI at 63.22 is Neutral, neither overbought nor oversold. The STOCH value of 86.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ALBERTDAVD.
Albert David Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | ₹3.56B | 19.99 | ― | ― | -5.82% | -59.22% | |
54 Neutral | ₹2.08B | -338,564.26 | ― | ― | 4.04% | -35.02% | |
53 Neutral | ₹2.65B | 7.63 | ― | ― | -30.27% | -3470.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹4.19B | 6.87 | ― | 0.66% | -13.51% | -122.00% | |
50 Neutral | ₹3.03B | -32.50 | ― | ― | 9.42% | -12220.00% | |
49 Neutral | ₹2.13B | 10.71 | ― | ― | 18.67% | ― |
* Healthcare Sector Average
IN:ALBERTDAVD
Albert David Ltd
734.55
-52.29
-6.65%
IN:BROOKS
Brooks Laboratories Limited
72.29
-60.11
-45.40%
IN:LYKALABS
Lyka Labs Limited
58.12
-45.48
-43.90%
IN:NECLIFE
Nectar Lifesciences Ltd.
11.82
-10.08
-46.03%
IN:VIKASLIFE
Vikas Lifecare Limited
1.63
-1.16
-41.58%
IN:ZIMLAB
Zim Laboratories Ltd.
73.07
-14.03
-16.11%
Albert David Ltd Corporate Events
Albert David Publishes Notice on Re-Lodgement of 300 Physical Shares
Mar 13, 2026
Albert David Ltd has disclosed that it received a request from investor Bharat Kumar N Jain for transfer of 300 physical equity shares into his name, relating to securities previously purchased but not transferred. In line with SEBI guidelines on ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.